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Background. Patients with impaired renal function can accu-
mulate strontium in the bone, which has been associated with
the development of osteomalacia. A causal role for strontium
in the development of the disease was presented in chronic re-
nal failure (CRF) rats. Strontium-ranelate has been put forward
as a therapeutic agent in the treatment of osteoporosis. Since
the target population for strontium treatment consists mainly in
postmenopausal osteoporotic women, who may have a reduced
renal function, the risk for osteomalacia should be considered.
Methods. To determine the time evolution and reversibility
of the strontium-induced mineralization defect, CRF rats were
loaded with strontium (2 g/L) (± 200 mg/kg/day) during 2, 6,
and 12 weeks, followed by a washout period of 0, 2, 4, or 8 weeks.
Results. Histologic examination of the bone of the animals
treated with strontium revealed signs of osteomalacia already
after 2 weeks. Animals that received strontium during 6 and
12 weeks had a significantly higher osteoid perimeter, area and
thickness as compared to CRF controls. After 12 weeks, the min-
eralization was significantly affected, as evidenced by a lower
double-labeled surface, mineral apposition and bone forma-
tion rate in combination with an increased osteoid maturation
time and mineralization lag time. The osteoblast perimeter was
significantly lower in the strontium-treated animals. After the
washout periods, these effects were reversed and the bone le-
sions evolved to the values of CRF controls. This went along
with an 18% reduction of the bone strontium content. A sig-
nificant rise in serum alkaline phosphatase (ALP) activity was
apparent in the strontium-treated animals as compared to CRF
controls. This was not only due to higher levels of the bone
ALP but also to those of the liver and the intestinal isoen-
zymes. Serum parathyroid hormone (PTH) levels decreased
during strontium treatment. After cessation of the treatment,
the serum ALP activity and PTH concentration reversed to con-
trol levels.
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Conclusion. In this study evidence is provided for the rapid
development of a mineralization defect in strontium-loaded
CRF rats, accompanied by a reduced osteoblast number, re-
duced PTH synthesis or secretion, and increased serum ALP
levels. These effects can be rapidly reversed after withdrawal of
the compound.
Experimental studies in animals with normal renal
function have demonstrated strontium to exert benefi-
cial as well as adverse effects on bone, depending on the
dose administered [1]. Data in literature indicate that a
high dietary intake of strontium may disturb bone min-
eralization and induce bone abnormalities [2–9]. In rats
with intact renal function, the development of rickets was
induced after adding the element to the animals’ drink-
ing water at a concentration of 4 g/L (± 400 mg/kg/day,
as extrapolated from the weight and daily fluid intake
of adult rats) [3, 10]. In contrast, there is experimental
evidence that strontium administration at low doses re-
duces bone resorption and increases bone formation, re-
sulting in increased bone mass in normal animals. Doses
lower than 4 g/L of oral stable strontium have been shown
to stimulate bone formation without altering bone re-
sorption in the rat with normal renal function. This ob-
servation was found to be due to a strontium-induced
stimulation of the osteoblastic activity evidenced by an
increase in the amount of osteoid that was observed in
the absence of any mineralization defect or any change
in osteoclastic surface or number [3, 10–13]. Strontium,
as the ranelate compound, has been shown to act as an
uncoupling agent thereby increasing bone formation and
reducing bone resorption, leading to a gain of bone mass
and improving bone mechanical properties in ovariec-
tomized rats (77 to 308 mg/kg/day during 60 days) [12],
immobilized rats (800 mg/kg/day during 2 weeks), mice
(200 to 1800 mg/kg/day during 104 weeks) [14] and mon-
keys (750 mg/kg/day during 6 months) [15]. In view of
these findings, strontium-ranelate has been proposed as a
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potential agent in the treatment of bone diseases that are
characterized by a desequilibrium of the bone remodeling
process, such as osteoporosis [16–21]. In a recent phase
3 clinical trial, 3 years of strontium-ranelate treatment
(2 g/day) (± 30 mg/kg/day) has been shown to produce an
early and sustained reduction in the risk of vertebral frac-
tures in women with postmenopausal osteoporosis [22,
23]. However, as the above studies were performed in ani-
mals and humans with normal renal function and because
the main route of elimination of strontium is the kidney
[24], the risk for side effects due to an increased accu-
mulation of the element in bone should be considered in
elderly people, who already have a moderately decreased
renal function and constitute the target population for the
treatment of osteoporosis and osteoarthritis. In dialysis
patients, we previously showed an association between
increased bone strontium levels and the presence of os-
teomalacia [25–27]. Evidence for a causal role of the el-
ement in the development of the disease was presented
in chronic renal failure (CRF) rats [28, 29]. Indeed, oral
administration of strontium to CRF rats over a 12-week
period by adding the element to the drinking water at a
concentration of 3.4 g/L (± 340 mg/kg/day), resulted in
the development of distinct osteomalacic lesions in con-
trast to the animals that had not received the compound.
These effects appeared to be dose-dependent. Animals
that were given strontium in their drinking water at the
lowest dose (0.3 g/L) (± 30 mg/kg/day) exhibited charac-
teristics of low turn-over osteodystrophy (adynamic bone
disease) characterized by the absence of osteoblasts, a
dramatically reduced bone formation rate and decreased
amount of osteoid tissue. Rats that received a 0.75 g/L
(± 75 mg/kg/day) dose showed no significant abnormal-
ities. Rats receiving the highest strontium dose (1.5 g/L)
(150 mg/kg/day), however, developed a mineralization
defect, reflecting the histologic features of osteomalacia
[29]. This multiphasic effect of strontium on bone could
be reproduced in an in vitro setup of primary rat os-
teoblasts. Here, it was also shown that strontium at low
concentrations impairs the in vitro differentiation of os-
teoprogenitor cells toward mature osteoblasts and dis-
turbs mineralization at high concentrations [30].
The moderate renal failure that was induced in these
rats using the “remnant kidney” procedure is comparable
with the remaining renal function of some elderly people.
Data in literature indicate that in these patients the thera-
peutic administration of the compound at relatively high
doses (up to 2 g/day as proposed in clinical trials) may
lead to a distinct accumulation of the element in bone up
to values that are in the same order of magnitude as those
seen in uremic rats of our previous studies and plasma lev-
els (up to >10 mg/L [23]) that could clearly be associated
with the development of osteomalacia in CRF rats.
To further elucidate the mechanism underlying the
strontium-induced effect on bone, we studied the tempo-
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Fig. 1. Time scheme of the experimental study setup. CRF is chronic
renal failure; WO is washout.
ral development of the mineralization defect and inves-
tigated the reversibility of the bone lesion after cessation
of the strontium loading.
METHODS
Experimental design
CRF was induced in male Wistar rats weighing 150 to
200 g by applying the remnant kidney model (5/6 nephrec-
tomy) as previously described [28]. Two weeks after ini-
tiation of the renal failure, both control animals (N =
19), receiving no strontium and study animals receiving
2 g/L (± 200 mg/kg/day) strontium via the drinking water
(N = 60) were divided into different treatment groups
as shown in Figure 1. Control and strontium-loaded ani-
mals had free access to food and water. Water as well as
food consumption were recorded every 2 weeks. Blood
and urine samples were taken every 2 weeks. For 24-hour
urine collection the animals were housed individually in
metabolic cages. Blood was taken from the tail vein dur-
ing the study period and by aortic puncture at sacrifice.
Serum and urine samples were frozen at −80◦C until
analysis. At 7 and 3 days before sacrifice, rats were la-
beled with tetracycline (30 mg/kg) and demeclocycline
(25 mg/kg), respectively. At sacrifice, of each rat, one
tibia was removed for histomorphometric analysis and
one femur was used for the determination of strontium
and calcium.
Biochemical and chemical analyses
Creatinine, calcium, and phosphorus in the serum were
measured using a Vitros 950 AT Autoanalyser System
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(Ortho Clinical Diagnostics, Johnson & Johnson, Raritan,
NJ, USA). Creatinine in urine was determined according
to the Jaffe´ method, while the method of Bradford was
used to measure proteinuria and urinary phosphorus con-
centration was determined using a photometric method
(inorganic phosphate kit) (Merck, Darmstadt,
Germany). Intact parathyroid hormone (iPTH) was
determined using a rat PTH immunoradiometric assay
(IRMA) kit (Immutopics, Inc., San Clemente, CA,
USA). Alkaline phosphatase (ALP) activity was quan-
tified spectrophotometrically by measurement of the
release of p-nitrofenol from p-nitrophenylphosphate,
reflected by the change in absorbance at 405 nm over a
5-minute period. This procedure is based on the kinetic
method for measuring total ALP acknowledged by the
International Federation of Clinical Chemistry (IFCC)
[31].
The ALP isoenzymes were measured using an op-
timized agarose gel electrophoretic method, shown to
have a high accuracy, precision, and reproducibility [32].
This method consists of an electrophoresis on a commer-
cially available agarose gel (Beckman, Analis, Namur,
Belgium). The serum samples were pretreated with phos-
pholipase C for better separation of the liver and bone
ALP isoenzyme. Visualization of the fractions is done
by incubation of the agarose gel with 5-bromo-4-chloro-
3-indolyl phosphate (BCIP) and quantification is per-
formed by scanning the gel in a computerized densitome-
ter (Appraise, Beckman Instruments, Brea, CA, USA).
Strontium in serum, urine, and bone was analyzed
using a Zeeman 3030 atomic absorption spectrometer
equipped with an HGA-600 graphite furnace, an AS-
60 autosampler, and an Anadex DP-9500B silent scribe
printer, all from Perkin-Elmer (Norwalk, CT, USA). To
determine strontium in serum, samples were diluted four-
fold in a solution containing 0.5 mL/L Triton X-100 and
1 mL/L HNO3 solution, whereas urine samples were di-
luted 1:20 in a 2 mL/L HNO3 solution. Strontium in bone
was assessed after digestion with concentrated HNO3
[33]. Calcium determinations in urine and bone were
done by flame-AAS (model 3110) (Perkin-Elmer) after
diluting the samples 1:500 in reverse osmosis water to
which 1 g/L lanthanum nitrate was added to avoid chem-
ical and ionization interferences.
Bone histology
At sacrifice, left femur and tibia were freed from soft
tissue. From each rat, the femur was weighed immedi-
ately after removal of skin and muscle tissue and stored
at +4◦C until chemical analysis. The tibia was used for his-
tologic examination after 24 hours’ fixation in Burkhardt
solution and subsequent transfer to a 70% ethanol so-
lution until further processing. Bone samples were then
embedded in 100% methylmetacrylate. Longitudinal sec-
tions (5 lm) of the proximal tibia were cut with a Jung K
microtome and stained according to Goldner for descrip-
tive histology and unstained 10 lm sections were used for
visualization of the tetracycline labels. Bone histologic
data, as well as dynamic parameters, are reported us-
ing standardized nomenclature and definitions [34]. The
parameters measured include (1) total bone area (%),
the area of trabecular bone, including both mineralized
bone and osteoid, expressed as percentage of the total
bone tissue area; (2) osteoid area (%), the measured
area of osteoid expressed as percentage of the total bone
area; (3) osteoid width (lm), the mean width of surface
osteoid seams, calculated by dividing the measured os-
teoid area by the length of the osteoid seams; (4) osteoid
perimeter (%), the trabecular bone perimeter occupied
by osteoid as percentage of the total bone perimeter;
(5) eroded perimeter (%), the percentage of trabecular
bone perimeter with scalloped bone resorptive lacunae;
(6) double-labeled perimeter (%), the percentage of total
trabecular surface exhibiting a double fluorescent tetra-
cycline label; (7) mineral apposition rate (lm/day), the
rate by which bone is mineralized, calculated as the av-
erage distance between the midpoints of two consecutive
tetracycline labels, divided by the time interval between
the labeling periods; (8) mineralization lag time (days),
mean time interval between deposition and mineraliza-
tion of any infinitesimal volume of matrix, averaged over
the entire life span of the osteoid seam; (9) bone forma-
tion rate (lm2/mm2/day), the volume of bone formed per
unit of time, calculated as the product of mineral appo-
sition rate and mineralising surface; and (10) osteoblast
perimeter (%), percentage of osteoid perimeter covered
by cuboidal (active) osteoblasts.
Statistics
Statistical analysis of the data was done using the
Kruskal-Wallis test and the Mann-Whitney test for un-
paired comparisons, followed by Bonferroni correction
when more than two groups were compared. Data are
expressed as mean ± SEM. A P value < 0.05 was consid-
ered to be significant at a two-tailed level.
RESULTS
Biochemical and chemical data
Daily food and water consumption were compara-
ble between the study groups. Body weights steadily
increased during the observation period and did not
differ between the controls and the strontium-loaded
animals. Urinary output was higher after initiation of
renal failure, but was comparable for both control and
strontium-loaded animals. Serum creatinine measure-
ments in control animals before and after initiation
of the 5/6 nephrectomy indicate that a moderate de-
gree of renal failure was induced (Table 1). Fourteen
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Table 1. Biochemical parameters in serum and urine of the various study groups.
Control Strontium
Pre- CRF 2 weeks 6 weeks 12 weeks 2 weeks 6 weeks 12 weeks
Serum creatinine mg/dL 0.39 ± 0.10 1.01 ± 0.33a 0.94 ± 0.30a 1.67 ± 0.85a 1.00 ± 0.21a 1.19 ± 0.35a,b 1.20 ± 0.34a
Serum calcium mg/dL 9.95 ± 0.36 10.33± 0.40a 10.10 ± 0.41 10.13 ± 0.21 9.99 ± 0.40b 9.92 ± 0.68 10.03 ± 0.55
Serum phophorus mg/dL 7.00 ± 1.29 7.08 ± 0.98 5.64 ± 1.61a 6.72 ± 1.73 6.13 ± 1.67a,b 6.07 ± 1.83a,b 4.93 ± 2.05a
Creatinuria mg/24 hours 10.98 ± 2.48 9.58 ± 2.33 11.64 ± 2.14 10.40 ± 3.61 9.23 ± 1.53a 10.36 ± 2.30 10.50 ± 3.77
Creatinine clearance 0.78 ± 0.28 0.24 ± 0.08a 0.27 ± 0.09a 0.16 ± 0.12a 0.22 ± 0.06a 0.20 ± 0.07a 0.19 ± 0.07a
lL/min/100 g
Proteinuria mg/24 hours 8.14 ± 2.84 54.60 ± 50.10a 84.04 ± 49.19a 129.29 ± 70.33a 69.06 ± 46.37a,b 102.52 ± 45.54a,b 80.19 ± 49.36a
CFR is chronic renal failure.
aP < 0.05 versus pre-CRF; bP < 0.05 versus control.
weeks postsurgery, serum levels of creatinine were ele-
vated 4.3-fold and creatinine clearance was 78% lower
in the CRF rats as compared to the control animals. In-
duction of renal failure caused a rise in proteinuria in
both control animals and animals loaded with strontium
(Table 1). Serum calcium and phosphorus concentrations
were within the normal range and did not significantly
change during the course of the experiment, neither be-
tween groups. Strontium-loading did not affect serum
creatinine, calcium, or phosphate levels, neither did the
urinary creatinine excretion change during the course of
the experiment nor was it affected by treatment with
strontium (Table 1). Phosphaturia tended to decrease
during 2 and 6 weeks of strontium loading, which was
not reversed during the withdrawal period (Fig. 2A).
Strontium loading induced an increase in calciuria that
reversed to normal levels after withdrawal of the com-
pound (Fig. 2B).
Loading with strontium during 2, 6, and 12 weeks re-
sulted in a rise in the serum strontium concentration and
urinary strontium concentration, which decreased again
during the washout period (Fig. 3A and B). The rise of
serum strontium concentration was accompanied by a
time-dependent accumulation of the element in bone, as
indicated by the bone strontium concentrations (Fig. 3C).
After withdrawal of strontium during 2, 4, or 8 weeks, a
limited but statistically significant decrease of the bone
strontium content was noted. From these data, the half-
time for removal of strontium from the bone was esti-
mated to be 9.7 ± 2.9 weeks.
As shown in Figure 4, comparison of the iPTH levels
before and after induction of renal failure revealed an
increase of this parameter, though not statistically signif-
icant. Strontium loading during 2, 6, or 12 weeks went
along with a decrease in serum PTH levels compared to
control animals, however, again rose to control values
during the washout period.
At sacrifice, control animals had lower serum ALP
activity, compared to values before initiation of renal
failure. Loading with strontium, however, caused a
significant increase in total serum ALP activity (80% in-
crease versus controls) after 2 weeks of strontium loading,
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281% after 6 weeks, and 77% after 12 weeks, which de-
creased again during the 2, 4, or 8 weeks washout periods
(Fig. 5A). It was further demonstrated that strontium in-
duced an increase in all three ALP isoenzymes, which was
statistically significant for liver and bone ALP (Fig. 5B to
D). The bone isoenzyme was the major contributor to the
total ALP measured in serum. All three forms decreased
again after withdrawal of strontium.
Histologic data
Rats treated with strontium for 6 and 12 weeks dis-
played significantly increased amounts of osteoid tissue
as evidenced by the increased osteoid perimeter, osteoid
area, and osteoid thickness (Fig. 6). The mineral appo-
sition rate, adjusted apposition rate, double-labeled sur-
face and bone formation rate decreased after 2, 6, and
12 weeks of strontium administration, which was accom-
panied by an increase in mineralization lag time and os-
teoid maturation time (Fig. 6). These data, together with
the increased amount of osteoid, provide evidence for
the development of a mineralization defect reflected by
the histologic picture of osteomalacia in the strontium-
loaded animals (Fig. 7). This was accompanied by a dra-
matic decrease in osteoblast perimeter during the various
loading periods (Figs. 6H and 7A to D). Administration
of strontium appeared to have no effect on osteoclast sur-
face or eroded perimeter, nor on the total bone area (data
not shown).
Mean urinary strontium concentration. (C) Bulk strontium concentra-
tion in bone. Values are expressed as mean ± SEM. aP < 0.05 versus
controls; bP < 0.05 versus strontium loading without washout.
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The amount of osteoid decreased already after 2 weeks
washout and reached normal values 4 (in the 12 weeks
loaded animals) or 8 (in the 6 weeks loaded animals)
weeks after strontium withdrawal. Cessation of stron-
tium administration went along with a significant increase
in the osteoblast perimeter after 8 weeks of washout in
animals that received strontium during 2 and 6 weeks.
As indicated by the histodynamic parameters, strontium
withdrawal also restored mineralization, an effect that
became significant after 2 and 4 weeks of washout in rats
that received strontium during a 12-week period.
DISCUSSION
Previously, we showed an association between in-
creased bone strontium levels and osteomalacia in bone
biopsies from 100 dialysis patients [25, 26]. Administra-
tion of the element to CRF rats induced a mineraliza-
tion defect that appeared to be dose-dependent [28, 29].
The experiment described in this paper was designed
to study the temporal evolution and reversibility of the
strontium-induced mineralization defect previously ob-
served in CRF animals.
We used the remnant kidney rat model, which is a well-
characterized model allowing the induction of a mild,
stable CRF, as reflected by the moderate increase in
serum creatinine levels and urinary protein excretion.
This mild renal failure can be compared to that ob-
served in some elderly people, including osteoporotic
postmenopausal women who constitute the target pop-
ulation for treatment with strontium-ranelate, a com-
pound that has recently been introduced on the market
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Fig. 6. Histologic data of the various study
groups. Data are as mean ± SEM. aP < 0.05
versus controls; bP < 0.05 versus strontium
(Sr) loading without washout (WO).
as an antiosteoporotic agent. As shown in Figure 1, rats
were administered strontium via the drinking water at a
2 g/L concentration, a dose at which a mineralization de-
fect has been induced in previous studies [29]). Indeed,
histomorphometric bone analysis of the animals treated
with strontium revealed clear signs of osteomalacia (a de-
fective mineralization in combination with an increased
osteoid volume) already after 2 weeks, which became sta-
tistically significant after 6 and 12 weeks. These data con-
firm our previous results concerning the development of
osteomalacia in strontium-treated CRF rats [29].
Moreover, in the rats treated with strontium, the
number of cuboidal osteoblasts already decreased after
2 weeks and further disappeared after 6 and 12 weeks.
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Fig. 7. Goldner-stained histologic bone samples and tetracycline labeling. (A) Normal bone histology in a 12-week control chronic renal fail-
ure (CRF) rat with large, cuboidal osteoblasts lining the osteoid tissue. (B) Bone histology of CRF rat after 12 weeks of strontium loading. There is an
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To which extent this is (1) either the result of the lower
iPTH levels seen in these groups, (2) due to a direct cell
biologic effect of strontium at the level of the osteoblast
as demonstrated in vitro [30], or (3) the consequence of a
combination effect of both is unclear. In this context the
ability of strontium to act on the osteoblast via a novel
cation-sensing mechanism, as suggested recently by Pi
and Quarles [35] is worth mentioning.
After 2 weeks of strontium loading, there was already
a limited increase in the amount of osteoid tissue, despite
a substantially decreased number of active, cuboidal os-
teoblasts. At this time point, however, the effect of stron-
tium on the various parameters of bone mineralization is
much more pronounced. This suggests that a direct effect
of strontium on bone mineralization must have preceded
the element’s effect on the osteoblast. In other words, we
hypothesize that in the early phase of strontium expo-
sure, osteoblasts secrete osteoid matrix at a reduced rate
that, however, is not mineralized in an optimal way. Ulti-
mately, this results in the histologic picture of osteomala-
cia, reflecting an imbalance between osteoid deposition
and mineralization.
In contrast to other studies in both rats and mice with
normal renal function, in which strontium treatment re-
sulted in a decreased osteoclast surface/number [11, 12],
no significant histologic effect of strontium on bone re-
sorption was shown in the present study.
Measurement of the bone strontium concentration re-
vealed that administration of strontium was accompanied
by a time-dependent accumulation of the element in the
bone. Even after 12 weeks of treatment, there was still
incorporation of the element, indicating that the bone
strontium content had not yet reached a plateau level.
Serum strontium concentrations, however, reached max-
imal values already after 2 weeks of strontium admin-
istration, and remained stable during the whole loading
period. In rats with normal renal function, Dahl et al [36]
also showed that the plasma strontium level reaches a
steady state within 10 days.
Withdrawal of strontium from the diet was accompa-
nied by a very rapid decrease of the serum strontium con-
centration, almost to control levels after 8 weeks washout,
and a substantial decrease (± 18%) of bone strontium.
Based on the data of the present study, the half-life of
strontium in bone was calculated to be 9.7 ± 2.9 weeks.
Because of the limited observation periods it was not pos-
sible to check whether the elimination of strontium out of
bone is linear over time or takes place via a multiphasic
way.
increased amount of osteoid tissue without the presence of active osteoblasts. (C) Bone histology of a CRF rat after 12 weeks of strontium loading,
followed by a washout period of 2 weeks. Large amounts of osteoid tissue are still present but osteoblasts have reappeared. (D) Bone histology
of a CRF rat after 12 weeks of strontium loading, followed by a washout period of 4 weeks. Active osteoblasts are lining a normal amount of
osteoid tissue. (E) Fluorescent tetracycline labeling in a CRF rat after 12 weeks of strontium loading. No labels are incorporated, which indicates
the development of a mineralization defect. (F) Tetracycline labeling in a 12-week control CRF rat. Normal double labels are present.
In the 12 weeks control group, serum levels of PTH
were elevated approximately twofold, indicating the de-
velopment of a mild secondary hyperparathyroidism and
reflecting the situation in humans with moderate CRF.
In animals treated with strontium, at all time points a
decrease of serum iPTH was found. Previously, it has
already been suggested that strontium may exert a cal-
cimimetic effect at the level of the calcium-sensing re-
ceptor, resulting in a decreased PTH secretion in rats
with normal renal function [37] and in bovine parathy-
roid cells in vitro [38]. Aside from the parathyroid gland,
the calcimimetic effect of strontium may also be active
at the level of the kidney. Indeed, the increased calciuria
might at least in part result from decreased tubular cal-
cium reabsorption in strontium-treated animals. More-
over, the decreased phosphaturia found after strontium
loading may be related to the reduced PTH levels in these
groups, since lowering PTH stimulates tubular phosphate
reabsorption [39].
The total serum ALP activity was significantly higher
in the animals treated with strontium. This is in agree-
ment with other studies in which higher serum total
ALP levels were also found after strontium admin-
istration to ovariectomized [12] and immobilized rats
[40]. Higher bone-specific ALP was also found after
strontium-ranelate treatment in osteoporotic women
[23]. In this context, however, it should be mentioned that
the measurement of total serum ALP encompasses the
codetermination of multiple other isoenzymes derived
from several other tissues such as the small intestine,
liver, and kidney. Therefore, the total serum ALP does
not always correlate with the bone isoenzyme, neither
with bone histologic parameters [41, 42]. In the present
study, measurement of the ALP isoenzymes indicated
that strontium loading is not only associated with an in-
creased concentration of the bone ALP, but of the in-
testinal and liver ALP isoenzymes as well. The exact
mechanism underlying this phenomenon is not yet clear
and could be attributable to an effect of strontium on the
synthesis of ALP, its release into the serum, its enzymatic
activity or to a decrease in the metabolic clearance rate of
this enzyme. Previously, we investigated the direct inter-
action of strontium with the ALP enzymatic activity by
incubating a human serum sample with different stron-
tium concentrations and we found no difference in the
electrophoretic mobility or enzymatic activity [30]. This
was confirmed after adding various amounts of strontium
to rat serum in the present study (data not shown). An
effect of strontium on the metabolic clearance rate of
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ALP is also highly unlikely, because all three isoforms
are affected in the same way by strontium administration.
Whether strontium may aspecifically promote hydrolysis
of the membrane anchoring of ALP deserves further in-
vestigation. These data indicate, however, that increased
concentrations of bone-specific ALP in serum are not
necessarily a reflection of an increased osteoblast num-
ber or activity.
After cessation of strontium treatment, the effects of
strontium on ALP and PTH were reversed and the his-
tologic and histodynamic parameters evolved to control
levels during the subsequent washout periods of 2, 4, or
8 weeks. To a certain extent, these findings are in line
with those of Johnson, Armstrong, and Singer [43], ob-
tained in young rats with normal renal function, show-
ing that during a washout period of 35 days, following a
28-day dietary strontium treatment (0.45% strontium),
the excess osteoid was catabolized and the bone trabec-
ulae evolved to a more normal appearance.
Data of the present study do not allow us to define
the exact mechanism by which strontium induces a bone
mineralization defect. The rapid development of this de-
fect, however, is compatible with the ability of strontium
to compete with calcium to form complexes with organic
components of the mature osteoid matrix such as phos-
pholipids, glycosaminoglycans, and phosphoproteins that
may act as nucleation points for crystal development and
growth [6]. Evidence for such a mechanism is further pro-
vided by the finding that, once circulating strontium levels
are lowered by withdrawal of the element, remineraliza-
tion rapidly occurs, despite the elevated levels at which
strontium is still present in bone.
Apart from this, other mechanisms by which stron-
tium may interfere with the bone mineral have to be
considered. During (impaired) apatite formation, stron-
tium may still be incorporated in the crystal lattice by
heteroionic exchange with calcium as indicated by previ-
ous observations demonstrating the element to be mainly
present in proximity of the mineralization front [28] (i.e.,
in newly formed bone [44]). Once entrapped in the crys-
tal lattice, removal of the element will reasonably be slow
and will mainly occur via osteoclastic resorption; a notion
being in line with the high bone strontium levels that are
still present after washout. To which extent the incorpo-
rated strontium, in the long run, may affect the crystal lat-
tice stability or bone strength deserves further investiga-
tion. In this context it is worth mentioning that, given the
anatomic heterogeneity of bone, local strontium concen-
trations may be reached at which, using X-ray diffraction
(XRD) and Fourier-transformed infrared spectroscopy
(FTIR) analysis, we recently showed reduced crystallinity
and altered crystal lattice [45].
Finally, the rapid accumulation and rapid partial re-
moval (± 18%) of the element after withdrawal is indica-
tive for a heteroionic exchange with calcium at the level of
the hydration shell surrounding the apatite crystal. This
hydration shell is considered the major site for fast ionic
exchange between the extracellular fluid and the miner-
alized bone compartment by which influx/efflux of stron-
tium may occur at both the mineralizing and quiescent
bone surfaces [46]. Localisation of strontium at this site
most probably has no deleterious effect on bone.
CONCLUSION
In this study evidence is provided for the rapid devel-
opment of a mineralization defect in strontium-loaded
CRF rats, accompanied by a reduced osteoblast number,
reduced PTH synthesis or secretion, and increased serum
ALP levels. These effects can be rapidly reversed after
withdrawal of the compound.
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